Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

Part of paid clinical trials in Brooksville, Florida.

Sponsor
GlaxoSmithKline
Study ID
NCT06979323
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Depemokimab — BIOLOGICAL
    Depemokimab will be administered.

Study Details

Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.

Key Dates

Start date
Jun 3, 2025
Status verified
Apr 2026
Primary completion
Dec 8, 2027
Completion
Feb 11, 2028

Study Design

Enrollment
150 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Depemokimab
    Participants with asthma with type 2 inflammation will receive depemokimab.

Primary Outcome Measure

Mean Change from Baseline in Total Mucus Plug Volume Measured at Total Lung Capacity (TLC) at Week 26 [ Time Frame: From Baseline up to Week 26 ]

Central Contacts

Locations (9)

FacilityCityStateZIPSite coordinators
GSK Investigational SiteBrooksvilleFlorida34613
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Salman Muddassir (PRINCIPAL_INVESTIGATOR)
GSK Investigational SitePlantationFlorida33324
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Frank Hull (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteKansas CityKansas66160
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Mario Castro (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteSt LouisMissouri63110
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
James Krings (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteNew BrunswickNew Jersey08901
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Reynold Panettieri (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteNew YorkNew York10029
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Monica Kraft (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteDuBoisPennsylvania15801
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Sandeep Bansal (PRINCIPAL_INVESTIGATOR)
GSK Investigational SitePhiladelphiaPennsylvania19140-5103
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Kartik Shenoy (PRINCIPAL_INVESTIGATOR)
GSK Investigational SiteMcKinneyTexas75069
US GSK Clinical Trials Call Center
[email protected]
877-379-3718
EU GSK Clinical Trials Call Centre
[email protected]
+44 (0) 20 8990 4466
Shahrukh Kureishy (PRINCIPAL_INVESTIGATOR)

Find similar trials in Brooksville, FL

By condition
Asthma
By specialty
PulmonologyLung disease
By research site
GSK Investigational Site· Brooksville, FLGSK Investigational Site· Plantation, FLGSK Investigational Site· Kansas City, KSGSK Investigational Site· St Louis, MOGSK Investigational Site· New Brunswick, NJGSK Investigational Site· New York, NY

Related Studies